Residency · Residency · Nuclear Medicine

Captopril Renography for Renovascular Hypertension

Overview

ACE inhibitor (captopril) renography is a functional test for detecting hemodynamically significant renal artery stenosis. It exploits the angiotensin II-dependent maintenance of GFR in a kidney with renal artery stenosis. Although its clinical use has declined with advances in CTA and MRA, captopril renography retains a unique role in assessing the functional significance of anatomically detected stenosis.

Pathophysiology

Renovascular Hypertension Mechanism

Renal artery stenosis reduces perfusion pressure to the affected kidney. Juxtaglomerular cells release renin, activating the renin-angiotensin-aldosterone system. Angiotensin II constricts the efferent arteriole to maintain GFR despite reduced renal perfusion. This compensatory mechanism preserves the filtration fraction in the stenotic kidney.

Effect of ACE Inhibition

ACE inhibitors such as captopril block angiotensin II production. Efferent arteriolar tone drops, reducing the filtration pressure gradient. GFR falls in the affected kidney, unmasking the stenosis. The contralateral normal kidney is unaffected or improves. The renogram pattern in the affected kidney deteriorates after captopril administration.

<image>Pathophysiology diagram showing the effect of ACE inhibition on glomerular filtration in a kidney with renal artery stenosis: loss of efferent arteriolar tone leading to reduced GFR</image>

Protocol

Patient Preparation

ACE inhibitors and ARBs are discontinued for 3 to 7 days before the study to eliminate baseline ACE inhibition. Diuretics are stopped for 1 to 3 days because dehydration can cause false positives. Adequate hydration with 500 to 1,000 mL of oral fluids before the study is essential. Blood pressure is checked before and during the study. Other antihypertensive medications are held if clinically safe.

Study Protocol

A baseline renogram using Tc-99m MAG3 (or DTPA) is performed without captopril. A captopril renogram is then repeated after 25 to 50 mg of oral captopril given 1 hour before tracer injection. Both studies may be performed on the same day (captopril study first, then baseline after washout) or on separate days. An alternative is a single-day captopril-only protocol when the baseline is normal, since a positive captopril study alone is diagnostic.

Imaging Parameters

Dynamic acquisition uses 1 to 2 minute frames for 30 minutes. Regions of interest are placed over each kidney and background regions. Time to peak (Tmax), half-time (T1/2), and differential renal function are calculated for both studies.

Interpretation Criteria

Positive (Suggests Hemodynamically Significant RAS)

With MAG3, a positive study shows prolonged cortical retention with Tmax exceeding 6 minutes on the captopril study, decreased differential function of the affected kidney after captopril, and delayed or absent excretion compared with baseline. With DTPA, findings include decreased GFR in the affected kidney after captopril, prolonged parenchymal transit time, and reduced differential function.

Specific Criteria for Positive Study

Specific criteria include a Tmax increase of more than 2 minutes after captopril compared with baseline, a significantly increased cortical retention ratio (20-minute-to-peak ratio), a decrease in differential function of more than 5% on the affected side, and prolonged washout T1/2 on the captopril study.

Negative Study

A negative study shows no significant change in renogram pattern between baseline and captopril studies. Both kidneys demonstrate symmetric function and drainage. This suggests that any anatomic stenosis is not hemodynamically significant.

<image>Captopril renography showing a normal baseline renogram bilaterally (left panel) and marked deterioration of the left kidney curve after captopril with cortical retention and prolonged Tmax (right panel), consistent with left renal artery stenosis</image>

Sensitivity and Specificity

The sensitivity ranges from 85 to 95% and the specificity from 80 to 95% for detecting hemodynamically significant renal artery stenosis. Performance is best with unilateral stenosis and a normal contralateral kidney. Accuracy is reduced with bilateral renal artery stenosis (where both kidneys deteriorate, making comparison difficult) and with impaired baseline renal function (GFR below 30 mL/min).

Limitations and Pitfalls

Bilateral Renal Artery Stenosis

When both kidneys have stenosis, both may show similar deterioration after captopril. Without a normal contralateral kidney for comparison, a false-negative result may occur if changes are symmetric.

Impaired Renal Function

When the baseline renogram is already abnormal, detecting further deterioration is difficult. Poor tracer excretion limits assessment of drainage and cortical retention. MAG3 is preferred over DTPA in this setting due to its better extraction efficiency.

Medication Effects

ACE inhibitors and ARBs must be stopped before the study; otherwise the baseline already reflects ACE inhibition. Diuretics can cause dehydration and false-positive results. NSAIDs may interfere with prostaglandin-mediated renal blood flow.

Hypotension After Captopril

Blood pressure should be monitored, as significant hypotension can occur, especially in patients with bilateral stenosis or volume depletion. IV fluids and vasopressors should be available.

Controversy: Current Role of Captopril Renography

Declining Use

CTA and MRA provide direct anatomic visualization of renal artery stenosis with high accuracy and have largely replaced functional testing as the initial screening tool. Additionally, interventional options such as angioplasty and stenting have shown limited benefit in many patients, as demonstrated by the ASTRAL and CORAL trials.

Remaining Indications

Captopril renography remains useful for assessing the functional significance of anatomically detected stenosis, predicting blood pressure response to revascularization (a positive captopril renogram predicts a better response), evaluating patients who cannot undergo CTA or MRA (due to contrast allergy, renal insufficiency, or MRI contraindications), and monitoring after renal artery revascularization.

<image>Comparison of CTA showing anatomic renal artery stenosis with captopril renography demonstrating functional significance of the stenosis by asymmetric renogram deterioration</image>

Fibromuscular Dysplasia vs. Atherosclerotic RAS

Fibromuscular Dysplasia (FMD)

FMD affects younger patients, typically women aged 20 to 50, and involves the mid to distal renal artery with a characteristic "string of beads" appearance on angiography. Captopril renography is more reliable in FMD because disease is typically unilateral with a normal contralateral kidney. Patients with FMD also have a better response to revascularization.

Atherosclerotic RAS

Atherosclerotic stenosis affects older patients with cardiovascular risk factors and involves the ostial or proximal renal artery. It is often bilateral and associated with aortic atherosclerosis. Captopril renography is less reliable in this setting due to bilateral disease and baseline renal impairment. The benefit of revascularization is controversial, as the CORAL trial showed no significant benefit over medical therapy alone.

Clinical Pearls

Captopril renography tests functional significance, not just the anatomic presence, of renal artery stenosis.

A positive captopril renogram predicts improvement in blood pressure after revascularization.

ACE inhibitors and ARBs must be stopped for at least 3 days before the study to avoid a false-negative result.

Bilateral renal artery stenosis is the Achilles heel of captopril renography. It should be considered if both kidneys show symmetric deterioration.

In the era of the CORAL and ASTRAL trials, the clinical question is shifting from "is there renal artery stenosis?" to "will the patient benefit from revascularization?" Captopril renography answers the latter question better than anatomic imaging.

MAG3 is preferred over DTPA for captopril renography due to superior image quality in patients with potential renal impairment.

References

• Taylor, A. T. "Radionuclides in Nephrourology: Part 2." Journal of Nuclear Medicine, 2014.
• ACR-SNM-SPR Practice Guideline for ACE Inhibitor Renography.
• CORAL Investigators. New England Journal of Medicine, 2014.
• ASTRAL Investigators. New England Journal of Medicine, 2009.

Read this lecture as Markdown